Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$120.52 USD

120.52
784,847

-4.62 (-3.69%)

Updated Jul 17, 2024 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids

by Zacks Equity Research

FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.

The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna

by Zacks Equity Research

Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More

by Kinjel Shah

FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.

Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day.

Kinjel Shah headshot

FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids

by Kinjel Shah

The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.

Pfizer (PFE) Starts EU Submission of Variant-Adapted Vaccine

by Zacks Equity Research

Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.

Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics

by Zacks Equity Research

An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.

Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA

by Zacks Equity Research

Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.

Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.

Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News for Jun 9, 2022

by Zacks Equity Research

Companies in The News Are: THO,CPB,MRNA,INTC

FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab

by Zacks Equity Research

An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab

by Zacks Equity Research

Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.

Why Is Moderna (MRNA) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer (PFE) Leads as US Plans Kids' COVID Vaccination in June

by Zacks Equity Research

The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.

AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot

by Zacks Equity Research

AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.

Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA

by Zacks Equity Research

Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).

Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.

Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?

by Zacks Equity Research

Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.

Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.

Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.

Company News for May 12, 2022

by Zacks Equity Research

Companies in The News Are: MRNA, COIN, OXY, SWCH, DBRG

Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates

by Zacks Equity Research

Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.

J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk

by Zacks Equity Research

J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.